This program project grant application focuses on the human oncogenic herpesviruses, Epstein- Barr Virus (EBV) and Kaposi Sarcoma-associated Herpesvirus (KSHV), to identify the critical mechanisms by which these agents induce cancer and deregulate cell growth. EBV and KSHV are linked to multiple cancers in the human population. This proposal will study the role of several viral and cellular genes and proteins in modulating EBV- and KSHV-mediated oncogenesis. To identify the mechanisms responsible for the oncogenic properties of these viruses, the projects will characterize the basic molecular properties of viral proteins and their interactions with cellular proteins. The experiments will identify how viral proteins interact with cellular proteins to change their function. Furthermore, the potential therapeutic benefits of targeting viral and cellular proteins will be tested in cell culture assays and animal models. This application consists of five projects and two cores. Project 1 will utilize electron microscopy to analyze the structure of KSHV proteins and replication complexes. Project 2 will elucidate the role of a cellular deubiquitinase, UCHL1, in membrane trafficking and cell-cell communication of EBV-infected cells. Project 3 will investigate how KSHV modulates the tumor microenvironment and the cellular and viral proteins involved in these processes. Project 4 will examine KSHV carcinogenesis using novel mouse models and cell culture assays, and Project 5 will investigate how the EBV oncoproteins, LMP1 and LMP2, modulate the cellular proteome and cellular pathways to contribute to EBV-associated malignancies. Core A provides administrative support for the overall program, while Core B provides state-of-the-art genomics and viral and cellular gene profiling, as well as biostatistics support for all the projects in this application.

Public Health Relevance

This program project grant application focuses on the human oncogenic herpesviruses, Epstein- Barr Virus (EBV) and Kaposi Sarcoma-associated Herpesvirus (KSHV), to identify the critical mechanisms by which these agents induce cancer and deregulate cell growth. EBV and KSHV are linked to multiple cancers in the human population. This proposal will study the role of several viral and cellular genes and proteins in modulating EBV- and KSHV-mediated oncogenesis. To identify the mechanisms responsible for the oncogenic properties of these viruses, the projects will characterize the basic molecular properties of viral proteins and their interactions with cellular proteins. The experiments will identify how viral proteins interact with cellular proteins to change their function. Furthermore, the potential therapeutic benefits of targeting viral and cellular proteins will be tested in cell culture assays and animal models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA019014-38
Application #
9320693
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Daschner, Phillip J
Project Start
1997-05-01
Project End
2021-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
38
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
DeKroon, Robert M; Gunawardena, Harsha P; Edwards, Rachel et al. (2018) Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. MBio 9:
Nicholls, Thomas J; Nadalutti, Cristina A; Motori, Elisa et al. (2018) Topoisomerase 3? Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell 69:9-23.e6
El-Mallawany, Nader Kim; Kamiyango, William; Villiera, Jimmy et al. (2018) Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. J Glob Oncol :1-7
Selitsky, Sara R; Marron, David; Mose, Lisle E et al. (2018) Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. mSystems 3:
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Lyons, Danielle E; Yu, Kuan-Ping; Vander Heiden, Jason A et al. (2018) Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication. J Virol 92:
Bigi, Rachele; Landis, Justin T; An, Hyowon et al. (2018) Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 115:E11379-E11387
El-Mallawany, Nader Kim; Villiera, Jimmy; Kamiyango, William et al. (2018) Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer 13:33
Kobayashi, E; Aga, M; Kondo, S et al. (2018) C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes. mSphere 3:
Hopcraft, Sharon E; Pattenden, Samantha G; James, Lindsey I et al. (2018) Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 14:e1007267

Showing the most recent 10 out of 324 publications